TrialInvestigational new drugs2012
A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction.
David J Adelstein et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this papercites it